JP2023545009A5 - - Google Patents

Info

Publication number
JP2023545009A5
JP2023545009A5 JP2023520312A JP2023520312A JP2023545009A5 JP 2023545009 A5 JP2023545009 A5 JP 2023545009A5 JP 2023520312 A JP2023520312 A JP 2023520312A JP 2023520312 A JP2023520312 A JP 2023520312A JP 2023545009 A5 JP2023545009 A5 JP 2023545009A5
Authority
JP
Japan
Prior art keywords
composition
antigen
vaccine
protein
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2023520312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/053275 external-priority patent/WO2022072910A1/en
Publication of JP2023545009A publication Critical patent/JP2023545009A/ja
Publication of JP2023545009A5 publication Critical patent/JP2023545009A5/ja
Abandoned legal-status Critical Current

Links

JP2023520312A 2020-10-02 2021-10-02 ポリヌクレオチドワクチンおよびその使用方法 Abandoned JP2023545009A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063087118P 2020-10-02 2020-10-02
US63/087,118 2020-10-02
PCT/US2021/053275 WO2022072910A1 (en) 2020-10-02 2021-10-02 Polynucleotide vaccines and methods of using the same

Publications (2)

Publication Number Publication Date
JP2023545009A JP2023545009A (ja) 2023-10-26
JP2023545009A5 true JP2023545009A5 (cg-RX-API-DMAC7.html) 2024-10-09

Family

ID=80950948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520312A Abandoned JP2023545009A (ja) 2020-10-02 2021-10-02 ポリヌクレオチドワクチンおよびその使用方法

Country Status (8)

Country Link
US (1) US20250213679A1 (cg-RX-API-DMAC7.html)
EP (1) EP4221739A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545009A (cg-RX-API-DMAC7.html)
KR (1) KR20230127977A (cg-RX-API-DMAC7.html)
CN (1) CN116916949A (cg-RX-API-DMAC7.html)
AU (1) AU2021355496A1 (cg-RX-API-DMAC7.html)
CA (1) CA3197650A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022072910A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022009688A (es) 2020-02-07 2022-12-15 Rnaimmune Inc Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus.
TW202328166A (zh) 2021-08-11 2023-07-16 美商達冕生物有限公司 針對新型冠狀病毒感染之mRNA疫苗之組成物及方法
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN114736925B (zh) * 2022-04-21 2025-03-04 奥明(杭州)生物医药有限公司 用于病毒感染所致癌症的环形mRNA疫苗开发平台
WO2024097259A1 (en) * 2022-11-01 2024-05-10 RNAimmune, Inc. Composition and methods for mrna vaccines against novel omicron coronavirus infections
WO2024163503A1 (en) * 2023-01-31 2024-08-08 Imunon, Inc. Process for producing dna formulations with lipopolymer delivery systems
KR102752534B1 (ko) * 2023-10-04 2025-01-10 국방과학연구소 탄저균 및 보툴리눔 독소 a형의 동시 방어용 복합 항원 발현벡터, 및 이를 포함한 유전자 백신

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262898B (it) * 1992-03-23 1996-07-22 Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk
WO2000040273A2 (en) * 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide
EP1278551A2 (en) * 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
WO2009108891A2 (en) * 2008-02-29 2009-09-03 Egen, Inc. Modified poloxamers for gene expression and associated methods
TW201718001A (zh) * 2015-07-31 2017-06-01 拜耳動物保健有限公司 豬物種中增強之免疫反應

Similar Documents

Publication Publication Date Title
Berglund et al. Enhancing immune responses using suicidal DNA vaccines
US6964762B2 (en) Composition and method for stimulating immune response to pathogen using complex adenoviral vector
US7528223B2 (en) Antigens encoded by alternative reading frames from pathogenic viruses
Rajčáni et al. Current developments in viral DNA vaccines: shall they solve the unsolved?
US20020155127A1 (en) Genetic vaccine against human immunodeficiency virus
JP2023545009A (ja) ポリヌクレオチドワクチンおよびその使用方法
US7754201B2 (en) Method of vaccination through serotype rotation
JP2024511356A5 (cg-RX-API-DMAC7.html)
JP2011088864A (ja) インフルエンザウイルスに対するベクターワクチン
US20130302368A1 (en) Advanced Prime and Boost Vaccine
Chunling et al. Enhanced induction of SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by adenovirus boosting in BALB/c mice
CA2325345A1 (en) Medicaments for inducing cytotoxic t-cells
CN1269524C (zh) 胸腺素强化的遗传免疫方法
JP5635950B2 (ja) 免疫原性組成物および方法
AU2007203565B2 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
JP5898324B2 (ja) 改良型hcvワクチンおよびその使用方法
Seth et al. Development of Indian HIV-1 Subtype C Vaccine Candidates
Seth HIV-1 subtype C vaccine: waiting in wings for the human trials
NZ781654A (en) Vaccines against hepatitis b virus
AU2002348154A1 (en) Genetic vaccine against human immunodeficiency virus